

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/12, C07H 21/02, C12N 7/04, 15/40, 15/86	A1	(11) International Publication Number: WO 96/37220
		(43) International Publication Date: 28 November 1996 (28.11.96)
(21) International Application Number: PCT/US96/07457 (22) International Filing Date: 22 May 1996 (22.05.96) (30) Priority Data: 08/446,932 23 May 1995 (23.05.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/446,932 (CIP) Filed on 23 May 1995 (23.05.95) (71) Applicant (for all designated States except US): THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL [US/US]; 300 Bynum Hall, Chapel Hill, NC 27599 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): JOHNSTON, Robert, E. [US/US]; 101 Marin Place, Chapel Hill, NC 27516 (US). DAVIS, Nancy, L. [US/US]; 415 Sharon Road, Chapel Hill, NC 27514 (US). SIMPSON, Dennis, A. [US/US]; Apartment 50, 400 Davie Road, Carrboro, NC 27510 (US). (74) Agents: SIBLEY, Kenneth, D. et al.; Bell, Seltzer, Park & Gibson, P.O. Drawer 34009, Charlotte, NC 28234 (US).		(81) Designated States: AL, AM, AT, AT (Utility model), AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: cDNA CLONE FOR SOUTH AFRICAN ARBOVIRUS NO. 86		
(57) Abstract The present invention provides a recombinant DNA comprising a cDNA coding for an infectious South African Arbovirus No. 86 (S.A.AR86) virus RNA transcript and a heterologous promoter positioned upstream from the cDNA and operatively associated therewith. The present invention also provides an infectious RNA transcript encoded by the cDNA, and infectious attenuated viral particles produced from cells transfected with the RNA transcript encoded by the cDNA.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

cDNA CLONE FOR SOUTH AFRICAN ARBOVIRUS NO. 86

Field of the Invention

The present invention relates to live attenuated vaccines in general, and particularly relates to attenuated vaccines produced from South African Arbovirus No. 86 (S.A.AR86) virus.

5

Background of the Invention

This invention was made with government support under Grant No. 2-ROIA122186 (09-13) awarded by the National Institutes of Health. The government has certain rights in the invention.

South African Arbovirus No. 86 (S.A.AR86) is an isolate of Sindbis virus. S.A.AR 86 was originally isolated from mosquitoes. The virus is antigenically related to Sindbis virus and to two other Sindbis virus isolates, Girdwood S.A. and Ockelbo82. See, Malherbe et al., *South African Medical Journal*, 37:547 (1963) and Niklasson et al., *Am. J. Trop. Med. Hyg.* 33:1212 (1984), respectively. The latter is associated with a human disease, also known as Ockelbo. Sindbis virus is the prototype member of the alphavirus genus of the family Togaviridae. The Sindbis virus includes various strains, including S.A.AR86 and Sindbis AR339. The genome of Sindbis viruses consists of a single strand of RNA which contains the information for the viral genes, and which is infectious when introduced into the cytoplasm of cells.

20

Full-length cDNA clones of positive-strand RNA viruses are important tools for the study of the biology of viruses including Sindbis viruses. It is known with respect to several viral systems that *in vitro* transcripts of cDNA clones, and in some cases the cDNA itself, can initiate a complete and productive infectious cycle upon introduction into susceptible cells. See Racaniello et al., *Science* 214:916 (1981); Ahlquist et al., *Proc. Natl. Acad. Sci. USA* 81:7066 (1984); Kaplan et al., *Proc. Natl. Acad. Sci. USA* 82:8424 (1985); Mizutani et al., *J. Virol.* 56:628 (1985); van der Werf, *Proc. Natl. Acad. Sci. USA* 83:2330 (1986); Rice et al., *J. Virol.* 61:3809 (1987); and Vos et al., *Virology* 165:33 (1988). This has made it possible to test progeny virus for phenotypic

25

-2-

manifestations of directed mutations and recombinations which have been introduced into the cDNA clone. Pathogenesis studies with several positive-strand viruses, including the picornaviruses and the alphaviruses have been advanced significantly by the use of full-length cDNA clones.

5 As another useful application, live attenuated viral vaccines may be produced using full-length cDNA clones. Live attenuated viral vaccines are among the most successful means of controlling viral disease. However for some virus pathogens, immunization with a live virus strain may be either impractical or unsafe. Sindbis virus is subclinical in humans, but is closely related to other
10 viruses which do induce clinical diseases in humans, such as Ockelbo, an epidemic polyarthritis syndrome common in areas of Scandinavia and Northern Europe. Accordingly, Sindbis virus vaccines are desirable for producing an immunogenic response to such clinical diseases. Sindbis virus vaccines are also desirable as viral carriers in virus constructs which express genes encoding immunizing
15 antigens for other viruses. *See* U.S. Patent No. 5,217,879 to Huang et al. Huang et al. describes Sindbis infectious viral vectors. However, the reference does not describe the cDNA sequence of S.A.AR86 virus, or clones or viral vectors produced therefrom.

 Accordingly, there remains a need in the art for full-length cDNA
20 clones of positive-strand RNA viruses, such as the S.A.AR86 strain of Sindbis. In addition, there is a need in the art for full-length cDNA clones of S.A.AR86 encoding infectious RNA transcripts. Further, there remains a need in the art for cDNA clones of S.A.AR86 which encode RNA transcripts which may be used to produce infectious attenuated viral particles, and methods of producing such viral
25 particles.

Summary of the Invention

 As a first aspect, the present invention provides a recombinant DNA comprising a cDNA coding for an infectious South African Arbovirus No. 86 (S.A.AR86) virus RNA transcript and a heterologous promoter positioned
30 upstream from the cDNA and operatively associated therewith. The cDNA is selected from the group consisting of (i) cDNA having the sequence given herein

-3-

as SEQ ID NO.: 1, (ii) cDNA having the same RNA coding sequence as the cDNA given herein as SEQ ID NO.: 1, and (iii) cDNA according to (i) or (ii) above and further containing at least one attenuating mutation. Preferably at least one attenuating mutation is included in the cDNA, and more preferably at least
5 two attenuating mutations are included in the cDNA. Attenuating mutations may, for example, be provided in any of the nsP1, E2, and nsP2 coding regions of the cDNA. Preferably at least one silent mutation is included in the cDNA in addition to the attenuating mutation(s).

As a second aspect, the present invention provides an infectious
10 RNA transcript encoded by the cDNA.

As a third aspect, the present invention provides infectious attenuated viral particles containing the RNA transcript encoded by the cDNA.

The foregoing and other aspects of the present invention are explained in detail in the detailed description set forth below.

15 **Brief Description of the Drawings**

Figure 1 shows the relationship of the 3' half of the nsP3 gene among various Sindbis-like isolates.

Figure 2 shows the replacement of of the AR339-derived cDNAs into the plasmid pToto1101 background.

20 **Detailed Description of the Invention**

The South African Arbovirus No. 86 (S.A.AR86) viral clones employed in practicing the present invention are genomic clones which code for an RNA transcript, which RNA transcript is capable of producing live encapsidated S.A.AR86 virus when used to transfect a S.A.AR86 virus-permissive
25 cell.

S.A.AR86 virus-permissive cells are cells which, upon transfection with the viral RNA transcript, are capable of producing viral particles. The S.A.AR86 virus has a broad host cell range. Examples of suitable host cells include, but are not limited to Vero cells, baby hamster kidney (BHK-21) cells,
30 and chicken embryo fibroblast cells. Uptake of the RNA into the cells can be

-4-

achieved by any suitable means, such as for example, by treating the cells with DEAE-dextran, treating the cells with "LIPOFECTIN^{RM}", and by electrophoresis, with electrophoresis being the currently preferred means of achieving RNA uptake into the host cells.

5 The phrases "attenuating mutation" and "attenuating amino acid," as used herein, mean a nucleotide mutation or an amino acid coded for in view of such a mutation which result in a decreased probability of causing disease in its host (i.e., a loss of virulence), in accordance with standard terminology in the art. *See, e.g.,* B. Davis, et al., Microbiology 132 (3d ed. 1980), whether the mutation
10 be a substitution mutation or an in-frame deletion mutation. The phrase "attenuating mutation" excludes mutations which would be lethal to the virus.

The phrase "silent mutation" as used herein refers to mutations in the cDNA coding sequence which do not produce mutations in the corresponding protein sequence translated therefrom.

15 The cDNA clone has a sequence as given herein as SEQ ID NO.: 1. Alternatively, the cDNA clone may have a sequence which differs from the cDNA of SEQ ID NO.: 1, but which has the same RNA coding sequence as the cDNA given herein as SEQ ID NO.: 1. Thus, the cDNA clone may include one or more silent mutations. For example, the clone sequence may differ from the
20 wild-type S.A.AR86 sequence given herein as SEQ ID NO.: 1, by the inclusion of silent mutations at any or all of nucleotides 215, 3863, 5984, and 9113. The silent mutations at the foregoing nucleotides may be substitution or in-frame deletion mutations, such as for example, the substitution of guanine for adenine at nucleotide 215 of the cDNA sequence given herein as SEQ ID NO.: 1; or the
25 substitution of guanine for cytosine at nucleotide 3863 of the cDNA sequence given herein as SEQ ID NO.: 1; or the substitution of guanine for adenine at nucleotide 5984 of the cDNA sequence given herein as SEQ ID NO.: 1; or the substitution of cytosine for thymine at nucleotide 9113 of the cDNA sequence given herein as SEQ ID NO.: 1. In yet another embodiment, the cDNA clone has
30 a sequence according to either of the foregoing described sequences, but which also includes attenuating mutations. The attenuating mutations being described more fully hereinafter.

-5-

Promoter sequences and S.A.AR86 virus cDNA clones are operatively associated in the present invention such that the promoter causes the cDNA clone to be transcribed in the presence of an RNA polymerase which binds to the promoter. The promoter is positioned on the 5' end (with respect to the virion RNA sequence), or "upstream" from, the cDNA clone. An excessive number of nucleotides between the promoter sequence and the cDNA clone will result in the inoperability of the construct. Hence, the number of nucleotides between the promoter sequence and the cDNA clone is preferably not more than eight, more preferably not more than five, still more preferably not more than three, and most preferably not more than one. Examples of promoters which are useful in the cDNA sequences of the present invention include, but are not limited to T3 promoters, T7 promoters, and SP6 promoters. The DNA sequence of the present invention may reside in any suitable transcription vector. The DNA sequence preferably has a complementary DNA sequence bonded thereto so that the double-stranded sequence will serve as an active template for RNA polymerase. The transcription vector preferably comprises a plasmid. When the DNA sequence comprises a plasmid, it is preferred that a unique restriction site be provided 3' (with respect to the virion RNA sequence) to (i.e., "downstream" from) the cDNA clone. This provides a means for linearizing the DNA sequence to allow the transcription of genome-length RNA *in vitro*.

The cDNA clone can be generated by any of a variety of suitable methods known to those skilled in the art. A preferred method is the method set forth in U.S. Patent No. 5,185,440 to Davis et al., and Gubler et al., *Gene* 25:263 (1983), the disclosures of which are incorporated herein by reference in their entirety. Attenuating mutations of S.A.AR86 are identified by sequencing attenuated strains of the S.A.AR86 virus and comparing the sequence of the attenuated strain with the sequence of the corresponding wild-type virus. Serial passage techniques for the generation of attenuated strains may be carried out in accordance with known procedures. Preferably, the attenuated strains are generated by selecting strains at each passage during serial passage in cell culture which either grow rapidly or penetrate the cell more rapidly. This selection process, which reduces the number of serial passages required to obtain attenuated strains,

is known. See, e.g., Olmstead et al., *Science* 225:424 (1984); and Johnston et al., *Virology* 162:437 (1988). the disclosures of which are incorporated herein by reference in their entirety. cDNA clones may be modified to incorporate attenuating mutations by site-directed mutagenesis in accordance with known procedures. An exemplary technique is that of Kunkel *Proc. Natl. Acad. Sci. (USA)* 82:488 (1985). These same techniques may be used to join the heterologous promoter to the cDNA clone.

RNA is preferably synthesized from the DNA sequence *in vitro* using purified RNA polymerase in the presence of ribonucleotide triphosphates in accordance with conventional techniques.

Pharmaceutical compositions, such as vaccines, containing the S.A.AR86 clone of the present invention comprise an immunogenic amount of a live attenuated virus as disclosed herein in combination with a pharmaceutically acceptable carrier. An "effective immunogenic amount" is an amount of the attenuated virus sufficient to evoke an immune response in the subject to which the vaccine is administered. An amount of about 10^1 to about 10^5 plaque forming units per dose is believed to be suitable, depending upon the age and species of the subject being treated. Examples of suitable pharmaceutically acceptable carriers include, but are not limited to, sterile pyrogen-free water and sterile pyrogen-free physiological saline solution. Subjects which may be administered immunogenic amounts of the live attenuated viruses of the present invention include both human and animal (e.g., horse, donkey, mouse, hamster, or monkey) subjects. Administration may be by a suitable means, such as intraperitoneal, intracerebral or intramuscular injection.

Complimentary DNA clones of the S.A.AR86 virus are made in accordance with the procedures described herein, as supplemented with procedures known in the art. We employed as a starting material, the S.A.AR86 virus.

A first exemplary attenuating substitution mutation in a S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably isoleucine, at nsP1 amino acid residue 538.

-7-

A second exemplary attenuating substitution mutation in a S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably threonine, at E2 amino acid residue 304.

5 A third exemplary attenuating substitution mutation in a S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably lysine, at E2 amino acid residue 314.

10 A fourth exemplary attenuating substitution mutation in a S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably valine, at E2 amino acid residue 372.

15 A fifth exemplary attenuating substitution mutation in a S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably alanine, at E2 amino acid residue 376.

One embodiment of the present invention contains, in combination, said attenuating substitution mutations at E2 amino acid residues 304, 314, 372, and 376.

20 A sixth exemplary attenuating substitution mutation in a S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably glycine, at nsP2 amino acid residue 96.

25 A seventh exemplary attenuating substitution mutation in a S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably valine, at nsP2 amino acid residue 372.

One embodiment of the present invention contains, in combination, said attenuating substitution mutations at nsP2 amino acid residues 96 and 372.

30 An eighth exemplary attenuating substitution mutation in an S.A.AR86 clone useful in practicing the present invention is a substitution

-8-

mutation which codes for an attenuating amino acid, preferably leucine, at nsP2 amino acid residue 529.

A ninth exemplary attenuating substitution mutation in an S.A.AR86 clone useful in practicing the present invention is a substitution
5 mutation which codes for an attenuating amino acid, preferably asparagine, at nsP2 amino acid residue 571.

A tenth exemplary attenuating substitution mutation in an S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably arginine, at nsP2 amino acid
10 residue 682.

An eleventh exemplary attenuating substitution mutation in an S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably arginine, at nsP2 amino acid residue 804.

15 A twelfth exemplary attenuating substitution mutation in an S.A.AR86 clone useful in practicing the present invention is a substitution mutation which codes for an attenuating amino acid, preferably arginine, at nsP3 amino acid residue 22.

One embodiment of the present invention contains, in combination,
20 said attenuating substitution mutations at nsP2 amino acid residues 529, 571, 682, and 804, and at nsP3 amino acid residue 22.

The cDNA clones according to the present invention are useful for the preparation of pharmaceutical formulations, such as vaccines, as described above. In addition, the cDNA clones of the present invention are useful for
25 administration to animals for the purpose of producing antibodies to the S.A.AR86 virus, which antibodies may be collected and used in known diagnostic techniques for the detection of S.A.AR86 virus.

The following examples are provided to illustrate the present invention, and should not be construed as limiting thereof. In these examples, nt
30 means nucleotide.

-9-

EXAMPLE 1

Relationship of S.A.AR86 Clone to Other Sindbis Strains

At the nucleotide level, S.A.AR86 differs from the consensus sequence of Sindbis strain AR339 by 685 nucleotides (111 amino acids). From the
5 published Sindbis HR sequence (*See, Strauss et al., Virol. 133:92 (1984)*), S.A.AR86 differs by 704 nucleotides and 119 amino acids. S.A.AR86 differs from the sequence of Ockelbo82 (*See, Shirako et al., Virol. 182:753 (1991)*) by 430 nucleotides (67 amino acids). Included in these differences are several insertions and deletions present in S.A.AR86 relative to the Sindbis sequences The
10 relationship of the 3' half of the nsP3 gene among various Sindbis-like isolates is shown in Figure 1.

EXAMPLE 2

Observed Mortality in Mice Infected with S.A.AR86

When adult mice are inoculated intracerebrally (i.c.) with low doses
15 of S.A.AR86, 100% motality is observed. The methods employed for evaluating the instance mortality in mice are set forth in D. Russell, et al., *J. Virol. 63(4):1619 (1989)*, the disclosure of which is incorporated herein by reference in its entirety. This high mortality rate is unique among "Sindbis-like" viruses which are characteristically avirulent in adult mice. Also unique in the S.A.AR86 strain
20 is the cys substitution for the opal stop codon normally found between the nsP3 and nsP4 genes.

EXAMPLE 3

Construction of S.A.AR86 Clone

The S.A.AR86 clone is constructed by substituting partial cDNA
25 clones of S.A.AR86 genomic RNA into pTR5000, one of a series of Sindbis AR339 cDNA clones. Construction of pTR5000 (a full-length cDNA clone of Sindbis following the SP6 phage promoter and containing mostly Sindbis AR339 sequences) is accomplished by sequential replacement of AR339-derived cDNAs into the plasmid pToto1101 background, according to the technique described in

Rice et al., *J. Virol.* 61:3809 (1987). The replacement of the AR339-derived cDNAs into the plasmid pToto1101 background is shown in Figure 2.

Production of the cDNAs used in constructing pTR5000 has been described previously in Polo et al., *J. Virol.* 62:2124 (1988), as has the
5 construction of pTR2000, see Polo et al., *J. Virol.* 62:2124 (1988) and Polo et al., *J. Virol.* 64:4438 (1990). Nucleotide numbering follows that of Strauss et al. *Virol.* 133:92 (1984).

The StuI (nt8571) to SacII (nt11484) fragment of pToto1101 is removed and replaced with the analogous fragment from clone pSB4 to form
10 pTR2000, using the loss of the pToto1101 StuI site at nt10770 (a site not present in AR339) as a screen, as shown in Figure 2. The sequences of AR339 and pToto1101 are identical from nt11485 to the 3'-end (nt11703). Therefore, as shown in Figure 2, these 3' sequences are of AR339 origin. Construction of pTR3000 is accomplished by replacement of the BssHII (nt9804) to StuI (nt8571)
15 fragment of pSB3 into pTR2000 from which the analogous fragment had been removed. The AflII site found at nt8835 in pToto1101 but absent in AR339 is used to screen the recombinants. An AR339 fragment from pSB1, SpeI (nt5262) to BssHII, is used to replace the SpeI-BssHII fragment from pTR2000, using the AflII screen and forming pTR4000. To construct pTR5000, pSB5 is subcloned
20 into pUC119, and the PstI site at nt3953 is ablated using site-directed mutagenesis, as described in Kunkel, *Methods Enzymol.* 154:367 (1987), to change nt3950 from U to C. The ClaI (nt2713) to SpeI fragment is removed from the mutagenized subclone and for pTR5000, is used to replace the analogous fragment of pTR4000 using the ablated PstI site as a screen.

25 Partial cDNA clones of S.A.AR86 were obtained using classical reverse transcriptase (RT) procedures according to Polo et al., *J. Virol.* 62:2124 (1988), as well as RT-PCR protocols according to Heidner et al., *J. Virol.* 68:2683 (1994). These cDNA clones are used to replace analogous portions of the clone pTR5000, culminating in the construction of a full-length cDNA of the
30 S.A.AR86 genomic sequence downstream of an SP6 promoter and followed by a poly (A) tract and a unique XbaI site. During the course of replacing S.A.AR86 sequences into pTR5000, it was observed that the pTR5000 nonstructural proteins

-11-

are incompatible with those of S.A.AR86, so that the chimeric clones yielded transcripts which are not infectious for baby hamster kidney (BHK-21) cells. In addition, the restriction sites in the nonstructural region of S.A.AR86 are very different from the Sindbis AR339-based clones. The first complete S.A.AR86 clone, pS10, also failed to yield infectious transcripts.

The construction is repeated, beginning with pTR5000, using sequences derived from the same partial cDNA clones of S.A.AR86 as are used for the construction of pS10 except for nucleotides 3171 to 6410 (numbering from nucleotide 1 of the S.A.AR86 sequence), which are derived by RT-PCR of the genomic RNA. The resulting construct, pS22, gives infectious transcripts, but the virus derived therefrom is temperature-sensitive. Replacement of nucleotides 3171 to 6410 with an alternative RT-PCR derived cDNA corrected the temperature-sensitive defect, yielding clone pS24.

EXAMPLE 4

Observed Mortality in Mice Infected with S.A.AR86

Upon i.c. inoculation virus derived from pS24 is avirulent, whereas S.A.AR86 caused 100% mortality. Clearly, pS24 contained one or more mutations which were strongly attenuating. The complete sequence of pS24 was determined directly from pS24 and related clones. Comparison with the S.A.AR86 genomic RNA sequence reveals 5 mutations or clusters of mutations which are potentially associated with the avirulent phenotype of virus from pS24. These included the mutations or clusters of mutations indicated in clones pS56, pS51, and pS57, a mutation at nt278 A-C (nsP1 407 K-Q), and a mutation at nt5972 T-G (nsP3 228 N-S). While said nsP1 407 substitution alone is a lethal mutation, the viruses are viable when the mutation co-exists with a serine at the nsP3 amino acid residue 228. Clone pS24 is corrected by a combination of site-directed mutagenesis and replacement of specific pS24 sequences with cDNA fragments which do not contain the subject mutations. The resulting cDNA is pS55 which contains 5' and 3' untranslated sequences identical to S.A.AR86 genomic RNA, no coding differences with S.A.AR86 genomic RNA, and the 4

-12-

non-coding changes at nt 215 A-G, nt 3863 C-G, nt 5984 A-G, and nt 9113 T-C. Virus derived from pS55 is indistinguishable from native S.A.AR86 in tests of virulence, and growth in adult mice and by histopathological analysis of tissues from infected animals. These results, which are reported in Table 1 below, indicate that virus derived from clone pS55 accurately reflects native S.A.AR86 both in terms of coding sequence and *in vivo* phenotype.

Table 1
VIRULENCE IN MICE

	AGE OF MICE	S.A.AR86	S55	S56 ²	S51 ³
10	4 to 6 Weeks				
	Mortality	100%	100%	80%	20%
	AST ¹	6.36 ± 1.39	6.37 ± 1.4	9.37 ± 1.77	8.5 ± 0.7

¹Average Survival Time in days.

²Virus isogenic with S55 except at nucleotide 6 (C → A).

15 ³Virus isogenic with S55 except at nucleotide 1648 (C → T). This is nsP1 amino acid 538 (T → I). The isoleucine is the amino acid found in all other Sindbis isolates sequenced to date.

The 3 mutations or clusters of mutations in clones pS56, pS51, and pS57 are placed independently into the pS55 background. Virus derived from each of these clones is highly attenuated in adult mice inoculated i.c. In clone pS53, the mutations at nucleotides 6 and 1672 are combined, and the resulting virus is avirulent in the adult mouse model. The mutations in pS61 are present in pS48, an intermediate clone constructed during the repair of pS24. The virus from pS48 produced small plaques on BHK-21 cells. When these mutations are placed in the pS55 background, they also gave a highly attenuated phenotype. (S61, virus derived from pS61, gave 33.3% mortality (6 ± 4.2)).

The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. The invention is defined by the following claims, with equivalents of the claims to be included therein.

-13-

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Johnston, Robert E.
Simpson, Dennis
Davis, Nancy L.

(ii) TITLE OF INVENTION: cDNA Clone for South African Arbovirus No. 86

(iii) NUMBER OF SEQUENCES: 1

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Kenneth D. Sibley
(B) STREET: Post Office Drawer 34009
(C) CITY: Charlotte
(D) STATE: NC
(E) COUNTRY: USA
(F) ZIP: 28234

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Sibley, Kenneth D.
(B) REGISTRATION NUMBER: 31,665
(C) REFERENCE/DOCKET NUMBER: 5470-118

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (919) 881-3140
(B) TELEFAX: (919) 881-3175
(C) TELEX: 575102

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 11663 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATTGGCGGCG TAGTACACAC TATTGAATCA AACAGCCGAC CAATTGCACT ACCATCACAA	60
TGGAGAAGCC AGTAGTTAAC GTAGACGTAG ACCCTCAGAG TCCGTTTGTC GTGCAACTGC	120
AAAAGAGCTT CCCGCAATTT GAGGTAGTAG CACAGCAGGT CACTCCAAAT GACCATGCTA	180

ATGCCAGAGC ATTTTCGCAT CTGGCCAGTA AACTAATCGA GCTGGAGGTT CCTACCACAG	240
CGACGATTTT GGACATAGGC AGCGCACCGG CTCGTAGAAT GTTTTCCGAG CACCAGTACC	300
ATTGCGTTTG CCCCATGCGT AGTCCAGAAG ACCCGGACCG CATGATGAAA TATGCCAGCA	360
AACTGGCGGA AAAAGCATGT AAGATTACAA ACAAGAACTT GCATGAGAAG ATCAAGGACC	420
TCCGGACCGT ACTTGATACA CCGGATGCTG AAACGCCATC ACTCTGCTTC CACAACGATG	480
TTACCTGCAA CACGCGTGCC GAGTACTCCG TCATGCAGGA CGTGATACAT AACGCTCCCG	540
GAACTATTTA CCACCAGGCT ATGAAAGGCG TCGGACCCT GTACTGGATT GGCTTCGACA	600
CCACCCAGTT CATGTTCTCG GCTATGGCAG GTTCGTACCC TGCATACAAC ACCAACTGGG	660
CCGACGAAAA AGTCCTTGAA GCGCGTAACA TCGGACTCTG CAGCACAAAG CTGAGTGAAG	720
GCAGGACAGG AAAGTTGTCTG ATAATGAGGA AGAAGGAGTT GAAGCCCGGG TCACGGGTTT	780
ATTTCTCCGT TGGATCGACA CTTTACCCAG AACACAGAGC CAGCTTGCG AGCTGGCATC	840
TTCCATCGGT GTTCCACTTG AAAGGAAAGC AGTCGTACAC TTGCCGCTGT GATACAGTGG	900
TGAGCTGCGA AGGCTACGTA GTGAAGAAAA TCACCATCAG TCCCGGGATC ACGGAGAGAA	960
CCGTGGGATA CGCGGTACA AACAAAGCG AGGGCTTCTT GCTATGCAA GTTACCGATA	1020
CAGTAAAGG AGAACGGGTA TCGTTCCCGG TGTGCACGTA TATCCCGGCC ACCATATGCG	1080
ATCAGATGAC CGGCATAATG GCCACGGATA TCTCACCTGA CGATGCACAA AACTTCTGG	1140
TTGGGCTCAA CCAGCGAATC GTCATTAACG GTAAGACTAA CAGGAACACC AATACCATGC	1200
AAAATTACCT TCTGCCAATC ATTGCACAAG GGTTCAGCAA ATGGGCCAAG GAGCGCAAAG	1260
AAGATCTTGA CAATGAAAA ATGCTGGGCA CCAGAGAGCG CAAGCTTACA TATGGCTGCT	1320
TGTGGGCGTT TCGCACTAAG AAAGTGCACT CGTCTATCG CCCACCTGGA ACGCAGACCA	1380
TCGTAAGT CCCAGCCTCT TTTAGCGCTT TCCCATGTC ATCCGTATGG ACTACCTCTT	1440
TGCCCATGTC GCTGAGGCAG AAGATGAAAT TGGCATTACA ACCAAAGAAG GAGGAAAAAC	1500
TGCTGCAAGT CCCGGAGGAA TTAGTTATGG AGGCCAAGGC TGCTTTCGAG GATGETCAGG	1560
AGGAATCCAG AGCGGAGAAG CTCGAGAAG CACTCCCACC ATTAGTGGCA GACAAAGGTA	1620
TCGAGGCAGC TCGGAAGTT GTCTGCGAAG TGGAGGGGCT CCAGGCGGAC ACCGGAGCAG	1680
CACTCGTCGA AACCCGCGC GGTGATGTAA GGATAATACC TCAAGCAAAT GACCGTATGA	1740
TCGACAGTA TATCGTTGTC TCGCCGATCT CTGTGCTGAA GAACGCTAAA CTCGCACCAG	1800
CACACCCGCT AGCAGACCAG GTTAAGATCA TAACGCACTC CGGAAGATCA GGAAGGTATG	1860
CAGTCGAACC ATACGACGCT AAAGTACTGA TGCCAGCAGG AAGTGCCGTA CCATGGCCAG	1920
AATTCTTAGC ACTGAGTGAG AGCGCCACGC TTGTGTACAA CGAAAGAGAG TTTGTGAACC	1980
GCAAGCTGTA CCATATTGCC ATGCACGGTC CCGTAAGAA TACAGAAGAG GAGCAGTACA	2040
AGGTTACAAA GGCAGAGCTC GCAGAAACAG AGTACGTGTT TGACGTGGAC AAGAAGCGAT	2100
GCGTTAAGAA GGAAGAAGCC TCAGGACTTG TCCTTTCCGG AGAACTGACC AACCCGCCCT	2160
ATCACGAACT AGCTCTTGAG GGAAGTGAAGA CTCGACCCGC GGTCCCGTAC AAGGTTGAAA	2220

-15-

CAATAGGAGT GATAGGCACA CCAGGATCGG GCAAGTCAGC TATCATCAAG TCAACTGTCA	2280
CGGCACGTGA TCTTGTTACC AGCGGAAAGA AAGAAAAGT CCGCGAAATT GAGGCCGACG	2340
TGCTACGGCT GAGGGGCATG CAGATCACGT CGAAGACAGT GGATTGGTT ATGCTCAACG	2400
GATGCCACAA AGCCGTAGAA GTGCTGTATG TTGACGAAGC GTTCCGGTGC CACGCAGGAG	2460
CACTACTTGC CTTGATTGCA ATCGTCAGAC CCCGTAAGAA GGTAAGTACTA TGCAGAGACC	2520
CTAAGCAATG CGGATTCTTC AACATGATGC AACTAAAGGT ACATTTCAAC CACCCTGAAA	2580
AAGACATATG TACCAAGACA TTCTACAAGT TTATCTCCCG ACGTTGCACA CAGCCAGTCA	2640
CGGCTATTGT ATCGACACTG CATTACGATG GAAAAATGAA AACCACAAAC CCGTGCAAGA	2700
AGAACATCGA AATCGACATT ACAGGGGCCA CGAAGCCGAA GCCAGGGGAC ATCATCTGA	2760
CATGTTTCCG CGGGTGGGT AAGCAACTGC AAATCGACTA TCCCGGACAT GAGGTAATGA	2820
CAGCCGCGGC CTCACAAGGG CTAACCAGAA AAGGAGTATA TGCCGTCCGG CAAAAAGTCA	2880
ATGAAAACCC GCTGTACGCG ATCACATCAG AGCATGTGAA CGTGTGCTC ACCCGCACTG	2940
AGGACAGGCT AGTATGAAA ACTTTACAGG GCGACCCATG GATTAAGCAG CTCACTAACG	3000
TACCTAAAGG AAATTTTCAG GCCACCATCG AGGACTGGGA AGCTGAACAC AAGGGAATAA	3060
TTGCTGCGAT AACAGTCCC GCTCCCCGTA CCAATCCGTT CAGCTGCAAG ACTAACGTTT	3120
GCTGGGCGAA AGCACTGGAA CCGATACTGG CCACGGCCGG TATCGTACTT ACCGGTTGCC	3180
AGTGGAGCGA GCTGTTCCCA CAGTTTGCGG ATGACAAACC AACTCGGCC ATCTACGCTT	3240
TAGACGTAAT TTGCATTAAG TTTTTCGGCA TGGACTTGAC AAGCGGGCTG TTTTCCAAAC	3300
AGAGCATCCC GTTAACGTAC CATCCTGCCG ACTCAGCGAG GCCAGTAGCT CATTGGGACA	3360
ACAGCCCAGG AACACGCAAG TATGGGTACG ATCAGCCCGT TGCCGCCGAA CTCTCCCGTA	3420
GATTTCCGGT GTTCCAGCTA GCTGGGAAAG GCACACAGCT TGATTGTCAG ACGGGCAGAA	3480
CTAGAGTTAT CTCTGCACAG CATAACTTGG TCCCAGTGAA CCGCAATCTC CCTCACGCTT	3540
TAGTCCCCGA GCACAAGGAG AAACAACCCG GCCCGGTGCA AAAATTCTTG AGCCAGTTCA	3600
AACACCACTC CGTACTTGTC ATCTCAGAGA AAAAAATTGA AGCTCCCCAC AAGAGAATCG	3660
AATGGATCGC CCCGATTGGC ATAGCCGGCG CAGATAAGAA CTACAACCTG GCTTTCGGGT	3720
TTCCGCCGCA GGCACGGTAC GACCTGGTGT TCATCAATAT TGGAACATAA TACAGAAACC	3780
ATCACTTTCA ACAGTGCGAA GACCACGGCG CGACCTTGAA AACCTTTTCG CGTTCGGCCC	3840
TGAACTGCCT TAACCCCGGA GGCACCCTCG TGGTGAAGTC CTACGGTTAC GCCGACCGCA	3900
ATAGTGAGGA CGTAGTCACC GCTCTTGCCA GAAAATTGT CAGAGTGTCT GCAGCGAGGC	3960
CAGAGTGGT CTCAAGCAAT ACAGAAATGT ACCTGATTTT CCGACAATA GACAACAGCC	4020
GCACACGACA ATTCACCCCG CATCATTTGA ATTGTGTGAT TTCGTCCGTG TACGAGGGTA	4080
CAAGAGACGG AGTTGGAGCC GCACCGTCGT ACCGTACTAA AAGGGAGAAC ATTGCTGATT	4140
GTCAAGAGGA AGCAGTTGTC AATGCAGCCA ATCCACTGGG CAGACCAGGA GAAGGAGTCT	4200
GCCGTGCCAT CTATAAACGT TGGCCGAACA GTTTCACCGA TTCAGCCACA GAGACAGGTA	4260

-16-

CCGCAAACT GACTGTGTGC CAAGGAAAGA AAGTGATCCA CGCGTTGGC CCTGATTTC	4320
GGAAACACCC AGAGGCAGAA GCCCTGAAAT TGCTGCAAAA CGCCTACCAT GCAGTGGCAG	4380
ACTTAGTAAA TGAACATAAT ATCAAGTCTG TCGCCATCCC ACTGCTATCT ACAGGCATT	4440
ACGCAGCCGG AAAAGACCGC CTTGAGGTAT CACTTAACTG CTTGACAACC GCGTAGACA	4500
GAAGTATGC GGACGTAACC ATCTACTGCC TGGATAAGAA GTGGAAGGAA AGAATCGACG	4560
CGGTGCTCCA ACTTAAGGAG TCTGTAAGT AGCTGAAGGA TGAGGATATG GAGATCGACG	4620
ACGAGTTAGT ATGGATCCAT CCGGACAGTT GCCTGAAGGG AAGAAAGGGA TTCAGTACTA	4680
CAAAAGGAAA GTTGTATTCG TACTTTGAAG GCACCAAATT CCATCAAGCA GCAAAGATA	4740
TGGCGGAGAT AAAGGTCCTG TTCCCAAATG ACCAGGAAAG CAACGAACAA CTGTGTGCCT	4800
ACATATTGGG GGAGACCATG GAAGCAATCC GCGAAAAATG CCCGGTCGAC CACAACCCGT	4860
CGTCTAGCCC GCCAAAAACG CTGCCGTGCC TCTGTATGTA TGCCATGACG CCAGAAAGGG	4920
TCCACAGACT CAGAAGCAAT AACGTCAAAG AAGTTACAGT ATGCTCCTCC ACCCCCCTC	4980
CAAAGTACAA AATCAAGAAT GTTCAGAAGG TTCAGTGAC AAAAGTAGTC CTGTTTAACC	5040
CGCATACCCC CGCATTCTT CCCGCCGTA AGTACATAGA AGCACCAGAA CAGCCTGCAG	5100
CTCCGCCTGC ACAGGCCGAG GAGGCCCCG GAGTTGTAGC GACACCAACA CCACCTGCAG	5160
CTGATAACAC CTCGCTTGAT GTCACGGACA TCTCACTGGA CATGGAAGAC AGTAGCGAAG	5220
GCTCACTCTT TTCGAGCTTT AGCGGATCGG ACAACTACCG AAGGCAGGTG GTGGTGGCTG	5280
ACGTCCATGC CGTCCAAGAG CCTGCCCTG TTCCACCGCC AAGGCTAAAG AAGATGGCCC	5340
GCCTGGCAGC GGCAAGAATG CAGGAAGAGC CAACTCCACC GGCAAGCACC AGCTCTGCGG	5400
ACGAGTCCCT TCACCTTTCT TTTGATGGG TATCTATATC CTTCGGATCC CTTTTCGACG	5460
GAGAGATGGC CCGCTTGGCA GCGGCACAAC CCCCAGCAAG TACATGCCCT ACGGATGTGC	5520
CTATGTCTTT CGGATCGTT TCCGACGGAG AGATTGAGGA GTTGAGCCGC AGAGTAACCG	5580
AGTCGGAGCC CGTCTGTTT GGGTCATTG AACCGGGCGA AGTGAATCA ATTATATCGT	5640
CCCATCAGC CGTATCTTT CCACCACGCA AGCAGAGACG TAGACGCAGG AGCAGGAGGA	5700
CCGAATACTG TCTAACCGGG GTAGGTGGGT ACATATTTT GACGGACACA GGCCCTGGGC	5760
ACTTGCAAAA GAAGTCCGT CTGCAGAACC AGCTTACAGA ACCGACCTTG GAGCGCAATG	5820
TTCTGGAAAG AATCTAGCC CCGGTGCTG ACACGTCGAA AGAGGAACAG CTCAAATCA	5880
GGTACCAGAT GATGCCACCG GAAGCCAACA AAAGCAGGTA CCAGTCTCGA AAAGTAGAAA	5940
ACCAGAAAGC CATAACCACT GAGCGACTGC TTTCAGGGCT ACGACTGTAT AACTCTGCCA	6000
CAGATCAGCC AGAATGCTAT AAGATCACCT ACCCGAAACC ATCGTATTCC AGCAGTGTAC	6060
CAGCGAACTA CTCTGACCCA AAGTTTGCTG TAGCTGTTTG TAACAACTAT CTGCATGAGA	6120
ATTACCCGAC GGTAGCATCT TATCAGATCA CCGACGAGTA CGATGCTTAC TTGGATATGG	6180
TAGACGGGAC AGTCGCTTGC CTAGATACTG CAACTTTTTG CCCCAGCAAG CTAGAAAGTT	6240
ACCCGAAAAG ACACGAGTAT AGAGCCCCAA ACATCCGCAG TGCGGTTCCA TCAGCGATGC	6300

-17-

AGAACACGTT GCAAAACGTG CTCATTGCCG CGACTAAAAG AACTGCAAC GTCACACAAA	6360
TGCGTGAAGT GCCAACACTG GACTCAGCGA CATTCAACGT TGAATGCTTT CGAAAATATG	6420
CATGCAATGA CGAGTATTGG GAGGAGTTTG CCCGAAAGCC AATTAGGATC ACTACTGAGT	6480
TCGTTACCGC ATACGTGGCC AGACTGAAAG GCCCTAAGGC CGCCGCACTG TTCGCAAAGA	6540
CGCATAATTT GGTCCCATTG CAAGAAGTGC CTATGGATAG ATTCGTCATG GACATGAAAA	6600
GAGACGTGAA AGTTACACCT GGCACGAAAC ACACAGAAGA AAGACCGAAA GTACAAGTGA	6660
TACAAGCCGC AGAACCCCTG GCGACCGCTT ACCTATGCGG GATCCACCGG GAGTTAGTGC	6720
GCAGGCTTAC AGCCGTTTTG CTACCCAACA TTCACACGCT CTTTGACATG TCGGCGGAGG	6780
ACTTTGATGC AATCATAGCA GAACACTTCA AGCAAGGTGA CCCGCTACTG GAGACGGATA	6840
TCGCCTCGTT CGACAAAAGC CAAGACGACG CTATGGCGTT AACCGGCCTG ATGATCTTGG	6900
AAGACCTGGG TGTGGACCA CCACTACTCG ACTTGATCGA GTGCGCCTTT GGAGAAATAT	6960
CATCCACCCA TCTGCCACG GGTACCCGTT TCAAATTCGG GCGGATGATG AAATCCGGAA	7020
TGTTCTCAC GCTCTTTGTC AACACAGTTC TGAATGTCGT TATCGCCAGC AGAGTATTGG	7080
AGGAGCGGCT TAAACGTCC AAATGTGCAG CATTTATCGG CGACGACAAC ATTATACACG	7140
GAGTAGTATC TGACAAAGAA ATGGCTGAGA GGTGTGCCAC CTGGCTCAAC ATGGAGGTGA	7200
AGATCATTGA CGCAGTCATC GGCAGAGAC CACCTTACTT CTGCGGTGGA TTCATCTTGC	7260
AAGATTCCGT TACCTCCACA GCGTGTGCG TGGCGGACCC CTTGAAAAGG CTGTTTAAGT	7320
TGGGTAAACC GCTCCAGCC GACGATGAGC AAGACGAAGA CAGAAGACGC GCTCTGCTAG	7380
ATGAAACAAA GCGTGGTTT AGAGTAGGTA TAACAGACAC CTTAGCAGTG GCCGTGGCAA	7440
CTCGGTATGA GGTAGACAAC ATCACACCTG TCCTGCTGGC ATTGAGAACT TTTGCCCAGA	7500
GCAAAAGAGC ATTTCAAGCC ATCAGAGGGG AAATAAGCA TCTCTACGGT GGTCTAAAT	7560
AGTCAGCATA GTACATTCA TCTGACTAAT ACCACAACAC CACCACCATG AATAGAGGAT	7620
TCTTTAACAT GCTCGGCCG CGCCCCCTCC CAGCCCCAC TGCCATGTGG AGGCCGCGGA	7680
GAAGGAGGCA GCGGCCCCG ATGCTGCCC GCAATGGGCT GGCTTCCAA ATCCAGCAAC	7740
TGACCACAGC CGTCAGTGC CTAGTCATTG GACAGGCAAC TAGACCTCAA ACCCCACGCC	7800
CACGCCCCG GCGCGCCAG AAGAAGCAGG CGCCAAAGCA ACCACGAAG CCGAAGAAAC	7860
CAAAACACA GGAGAAGAAG AAGAAGCAAC CTGCAAACC CAAACCCGA AAGAGACAGC	7920
GTATGGCACT TAAGTTGGAG GCCGACAGC TGTTGACGT CAAAATGAG GACGGAGATG	7980
TCATCGGCA CGCACTGCC ATGGAAGGAA AGGTAATGAA ACCACTCCAC GTGAAAGGAA	8040
CTATTGACCA CCCTGTGCTA TCAAAGCTCA AATTCACCA GTCGTAGCA TACGACATGG	8100
AGTTCGCACA GTTGCCGGTC AACATGAGAA GTGAGGCGTT CACCTACACC AGTGAACACC	8160
CTGAAGGGTT CTACAACTGG CACCACGGAG CGGTGCAGTA TAGTGGAGGC AGATTTACCA	8220
TCCCCGCGG AGTAGGAGC AGAGGAGACA GTGGTCGTCC GATTATGGAT AACTCAGGCC	8280
GGGTTGTCGC GATAGTCCTC GGAGGGGCTG ATGAGGGAAC AAGAACC GCC CTTTCGGTCG	8340

-18-

TCACCTGGAA TAGCAAAGGG AAGACAATCA AGACAACCCC GGAAGGGACA GAAGAGTGGT	8400
CTGCTGCACC ACTGGTCACG GCCATGTGCT TGCTTGGAAA CGTGAGCTTC CCATGCAATC	8460
GCCCCCCAC ATGCTACACC CGCGAACCAT CCAGAGCTCT CGACATCCTC GAAGAGAACG	8520
TGAACCACGA GGCCTACGAC ACCCTGCTCA ACGCCATATT GCGGTGCCGA TCGTCCGGCA	8580
GAAGTAAAG AAGCGTCACT GACGACTTTA CTTTGACCAG CCCGTA CTG GGCACATGCT	8640
CGTACTGTCA CCATACTGAA CCGTGCTTTA GCCCCATTAA GATCGAGCAG GTCTGGGATG	8700
AAGCGGACGA CAACACCATA CGCATA CAG A CTTCGCCCA GTTTGGATAC GACCAAAGCG	8760
GAGCAGCAAG CTCAAATAAG TACCGCTACA TGTCGCTCGA GCAGGATCAT ACTGTCAAAG	8820
AAGGCACCAT GGATGACATC AAGATCAGCA CCTCAGGACC GTGTAGAAGG CTTAGCTACA	8880
AAGGATACTT TCTCCTCGCG AAGTGTCTC CAGGGGACAG CGTAACGGTT AGCATAGCGA	8940
GTAGCAACTC AGCAACGTCA TGCACAATGG CCCGCAAGAT AAAACCAAAA TTCGTGGGAC	9000
GGGAAAAATA TGACCTACCT CCCGTTACG GTAAGAAGAT TCCTTGACA GTGTACGACC	9060
GTCTGAAAGA AACCAACGCC GGCTACATCA CTATGCACAG GCCGGGACCG CATGCCTATA	9120
CATCCTATCT GGAGGAATCA TCAGGGAAAG TTTACGCGAA GCCACCATCC GGAAGAACA	9180
TTACGTACGA GTGCAAGTGC GGCATTACA AGACCGGAAC CGTTACGACC CGTACCGAAA	9240
TCACGGGCTG CACCGCCATC AAGCAGTGCG TCGCCTATAA GAGCGACCAA ACGAAGTGGG	9300
TCTTCAACTC GCCGACTCG ATCAGACACG CCGACCACAC GGCCCAAGGG AAATTGCATT	9360
TGCCTTTCAA GCTGATCCCG AGTACCTGCA TGGTCCCTGT TGCCACGCG CCGAACGTAG	9420
TACACGGCTT TAAACACATC AGCCTCCAAT TAGACACAGA CCATCTGACA TTGCTACCA	9480
CCAGGAGACT AGGGGCAAC CCGGAACCAA CCACTGAATG GATCATCGGA AACACGGTTA	9540
GAAACTTCAC CGTCGACCGA GATGGCCTGG AATACATATG GGGCAATCAC GAACCAGTAA	9600
GGGTCTATGC CCAAGAGTCT GCACCAGGAG ACCCTCACGG ATGGCCACAC GAAATAGTAC	9660
AGCATTACTA TCATCGCCAT CCTGTGTACA CCATCTTAGC CGTCGCATCA GCTGCTGTGG	9720
CGATGATGAT TGGCGTAAT GTTGCAGCAT TATGTGCC TG TAAAGCGCG CGTGAGTGCC	9780
TGACGCCATA TGCCCTGGCC CCAATGCGG TGATTCCAAC TTCGCTGGCA CTTTGTGCT	9840
GTGTTAGGTC GGCTAATGCT GAAACATTCA CCGAGACCAT GAGTTACTTA TGGTGAACA	9900
GCCAGCCGTT CTTCTGGGTC CAGCTGTGTA TACCTCTGCG CGCTGTCGTC GTTCTAATGC	9960
GCTGTTGCTC ATGCTGCCTG CCTTTTITAG TGGTTGCCGG CGCCTACCTG GCGAAGGTAG	10020
ACGCCTACGA ACATGCGACC ACTGTTCCAA ATGTGCCACA GATACCGTAT AAGGCACTTG	10080
TTGAAAGGGC AGGGTACGCC CCGCTCAATT TGGAGATTAC TGTCATGTCC TCGGAGGTTT	10140
TGCCTTCCAC CAACCAAGAG TACATTACCT GCAAATTCAC CACTGTGGTC CCCTCCCTA	10200
AAGTCAGATG CTGCGGCTCC TTGGAATGTC AGCCCGCCGC TCACGCAGAC TATACCTGCA	10260
AGGTCTTTGG AGGGGTGTAC CCCTTCATGT GGGGAGGAGC ACAATGTTTT TCGACAGTG	10320
AGAACAGCCA GATGAGTGAG GCGTACGTCG AATTGTCA GT AGATTGCGCG ACTGACCAG	10380

-19-

CGCAGGCGAT TAAGGTGCAT ACTGCCGCGA TGAAAGTAGG ACTGCGTATA GTGTACGGGA	10440
ACACTACCAG TTTCCTAGAT GTGTACGTGA ACGGAGTCAC ACCAGGAACG TCTAAAGACC	10500
TGAAAGTCAT AGCTGGACCA ATTCAGCAT TGTTTACACC ATTCGATCAC AAGGTCGTTA	10560
TCAATCGCGG CCTGGTGAC AACTATGACT TTCCGGAATA CGGAGCGATG AAACCAGGAG	10620
CGTTTGGAGA CATTCAAGCT ACCTCCTTGA CTAGCAAAGA CCTCATCGCC AGCACAGACA	10680
TTAGGCTACT CAAGCCTTCC GCCAAGAACG TGCATGTCCC GTACACGCAG GCCGCATCTG	10740
GATTCGAGAT GTGGAAAAAC AACTCAGGCC GCCCACTGCA GGAAACCGCC CCTTTTGGGT	10800
GCAAGATTGC AGTCAATCCG CTTGAGCGG TGGACTGCTC ATACGGGAAC ATTCCCATTT	10860
CTATTGACAT CCCGAACGCT GCCTTTATCA GGACATCAGA TGCACTACTG GTCTCAACAG	10920
TCAAATGTGA TGTCAGTGAG TGCACTTATT CAGCGGACTT CGGAGGGATG GCTACCCTGC	10980
AGTATGTATC CGACCGCGAA GGACAATGCC CTGTACATTC GCATTGAGC ACAGCAACCC	11040
TCCAAGAGTC GACAGTTCAT GTCCTGGAGA AAGGAGCGGT GACAGTACAC TTCAGCACCG	11100
CGAGCCCA CA GCGAACTTC ATTGTATCGC TGTGTGGTAA GAAGACAACA TGCAATGCAG	11160
AATGCAAACC ACCAGCTGAT CATATCGTGA GCACCCCGCA CAAAAATGAC CAAGAATTCC	11220
AAGCCGCCAT CTCAAAACT TCATGGAGTT GGCTGTTTGC CCTTTTCGGC GCGCCTCGT	11280
CGCTATTAAT TATAGGACTT ATGATTTTGG CTTGCAGCAT GATGCTGACT AGCACACGAA	11340
GATGACCGCT ACGCCCAAT GACCCGACCA GCAAACTCG ATGTACTTCC GAGGAACTGA	11400
TGTGCATAAT GCATCAGGCT GGTATATTAG ATCCCGCTT ACCGCGGGCA ATATAGCAAC	11460
ACCAAACTC GACGTATTTT CGAGGAAGCG CAGTGCATAA TGCTGCGCAG TGTTGCCAAA	11520
TAATCACTAT ATTAACCATT TATTCAGCGG ACGCCAAAAC TCAATGTATT TCTGAGGAAG	11580
CATGGTGAT AATGCCATGC AGCGTCTGCA TAACTTTTTA TTATTTCTTT TATTAATCAA	11640
CAAAATTTTG TTTTAAACAT TTC	11663

-20-

That Which Is Claimed Is:

1. A recombinant DNA comprising a cDNA coding for an infectious South African Arbovirus No. 86 (S.A.AR86) virus RNA transcript, and a heterologous promoter positioned upstream from said cDNA and operatively associated therewith.
5
2. The recombinant DNA according to Claim 1, wherein said cDNA is selected from the group consisting of (i) cDNA having the sequence given herein as SEQ ID NO.: 1, (ii) cDNA having the same protein coding sequence as the cDNA given herein as SEQ ID NO.: 1, and (iii) cDNA according
10 to (i) or (ii) above, and further comprising at least one attenuating mutation in said cDNA.
3. The recombinant DNA according to Claim 1, wherein said cDNA has the sequence given herein as SEQ ID NO.: 1.
4. The recombinant DNA according to Claim 1, further
15 comprising at least one attenuating mutation in said cDNA clone.
5. The recombinant DNA according to Claim 1, further comprising at least two attenuating mutations in said cDNA clone.
6. The recombinant DNA according to Claim 5, wherein each of said attenuating mutations are in the region selected from the group consisting
20 of the nsP1 coding region, E2 coding region, and nsP2 coding region.
7. The recombinant DNA according to Claim 1, further comprising at least one attenuating mutation selected from the group consisting of codons at nsP1 amino acid position 538 which specify an attenuating amino acid, codons at E2 amino acid position 304 which specify an attenuating amino acid,
25 codons at E2 amino acid position 314 which specify an attenuating amino acid, codons at E2 amino acid position 372 which specify an attenuating amino acid,

- codons at E2 amino acid position 376 which specify an attenuating amino acid,
codons at nsP2 amino acid position 96 which specify an attenuating amino acid,
codons at nsP2 amino acid position 372 which specify an attenuating amino acid,
codons at nsP2 amino acid position 529 which specify an attenuating amino acid,
5 codons at nsP2 amino acid position 571 which specify an attenuating amino acid,
codons at nsP2 amino acid position 682 which specify an attenuating amino acid,
codons at nsP2 amino acid position 804 which specify an attenuating amino acid,
and codons at nsP3 amino acid position 22 which specify an attenuating amino
acid.
- 10 8. The recombinant DNA according to Claim 7, wherein said
attenuating mutation comprises a substitution mutation.
9. The recombinant DNA according to Claim 8, wherein said
substitution mutation codes for isoleucine at nsP1 amino acid 538.
10. The recombinant DNA according to Claim 8, wherein said
15 substitution mutation codes for threonine at E2 amino acid 304.
11. The recombinant DNA according to Claim 8, wherein said
substitution mutation codes for lysine at E2 amino acid 314.
12. The recombinant DNA according to Claim 8, wherein said
substitution mutation codes for valine at E2 amino acid 372.
- 20 13. The recombinant DNA according to Claim 8, wherein said
substitution mutation codes for alanine at E2 amino acid 376.
14. The recombinant DNA according to Claim 8, wherein said
substitution mutation codes for glycine at nsP2 amino acid 96.

-22-

15. The recombinant DNA according to Claim 8, wherein said substitution mutation codes for valine at nsP2 amino acid 372.

16. The recombinant DNA according to Claim 8, wherein said substitution mutation codes for leucine at nsP2 amino acid 529.

5 17. The recombinant DNA according to Claim 8, wherein said substitution mutation codes for asparagine at nsP2 amino acid 571.

18. The recombinant DNA according to Claim 8, wherein said substitution mutation codes for arginine at nsP2 amino acid 682.

10 19. The recombinant DNA according to Claim 8, wherein said substitution mutation codes for arginine at nsP2 amino acid 804.

20. The recombinant DNA according to Claim 8, wherein said substitution mutation codes for arginine at nsP3 amino acid 22.

21. The recombinant DNA according to Claim 1 further comprising at least one silent mutation.

15 22. The recombinant DNA according to Claim 21, wherein said silent mutation is located at a position selected from the group consisting of nucleotide 215, nucleotide 3863, nucleotide 5984 and nucleotide 9113.

20 23. The recombinant DNA according to Claim 1, wherein not more than eight nucleotides are positioned between said promoter and said cDNA clone.

24. The recombinant DNA according to Claim 23, wherein said promoter is selected from the group consisting of T3 promoters, T7 promoters, and SP6 promoters.

-23-

25. The recombinant DNA according to Claim 1, wherein said recombinant DNA comprises a plasmid, and wherein said recombinant DNA further comprises a unique restriction site positioned downstream from said cDNA clone.

5 26. An infectious RNA transcript encoded by a cDNA according to Claim 1.

27. Infectious attenuated viral particles containing an RNA transcript of Claim 26.

10 28. A pharmaceutical composition comprising an effective immunogenic amount of an infectious attenuated virus according to Claim 27 in combination with a pharmaceutically acceptable carrier.




FIG. 1.




FIG. 2.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/07457

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : A61K 39/12; C07H 21/02; C12N 7/04, 15/40, 15/86 US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/235.1, 236, 320.1, 69.1; 424/93.1, 93.2, 93.6; 536/23,1, 23.72 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) APS, Dialog, Medline, Biotech, Biosis Search terms: alphavirus, Sindbis, arbovirus, vector, attenuated																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
A	US 5,217,879 A (HUANG et al.) 08 JUNE 1993, columns 1-2.	1-28																		
A	VOS et al. Infectious RNA transcripts derived from full-length DNA copies of the genomic RNAs of cowpea mosaic virus. Virology, 1988, Vol. 165, pages 33-41, especially page 34.	1-28																		
A	VAN DER WERF et al. Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. Proceedings of the National Academy of Sciences. April 1986, Vol. 83, pages 2330-2334, especially page 2331.	1-28																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"><tr><td>* Special categories of cited documents:</td><td>"T"</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>"A" document defining the general state of the art which is not considered to be of particular relevance</td><td>"X"</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>"E" earlier document published on or after the international filing date</td><td>"Y"</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>"&"</td><td>document member of the same patent family</td></tr><tr><td>"O" document referring to an oral disclosure, use, exhibition or other means</td><td></td><td></td></tr><tr><td>"P" document published prior to the international filing date but later than the priority date claimed</td><td></td><td></td></tr></table>			* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family	"O" document referring to an oral disclosure, use, exhibition or other means			"P" document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																		
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family																		
"O" document referring to an oral disclosure, use, exhibition or other means																				
"P" document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search 17 AUGUST 1996		Date of mailing of the international search report 05 SEP 1996																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer DAVID GUZO Telephone No. (703) 308-0196																		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/07457

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

435/235.1, 236, 320.1, 69.1; 424/93.1, 93.2, 93.6; 536/23,1, 23.72